Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Arformoterol tartrate
Drug ID BADD_D00160
Description Arformoterol is a bronchodilator. It works by relaxing muscles in the airways to improve breathing. Arformoterol inhalation is used to prevent bronchoconstriction in people with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. The use of arformoterol is pending revision due to safety concerns in regards to an increased risk of severe exacerbation of asthma symptoms, leading to hospitalization as well as death in some patients using long acting beta agonists for the treatment of asthma.
Indications and Usage A bronchodilator used for the long term, symptomatic treatment of reversible bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Marketing Status approved; investigational
ATC Code R03CC15; R03AC13
DrugBank ID DB01274
KEGG ID D02981
MeSH ID D000068759
PubChem ID 9827062
TTD Drug ID D0D1DI
NDC Product Code 64567-0022; 62332-633; 62756-277; 66039-909; 70748-175; 63402-911; 14501-0077; 0093-5955; 50384-4279; 70756-612; 69097-168; 53104-7731
UNII 5P8VJ2I235
Synonyms Formoterol Fumarate | Formoterol Fumarate, ((R*,R*)-(+-))-isomer | 3-Formylamino-4-hydroxy-alpha-(N-1-methyl-2-p-methoxyphenethylaminomethyl)benzyl alcohol.hemifumarate | BD 40A | Formoterol | Eformoterol | Oxis | Arformoterol | Formoterol, ((R*,R*)-(+-))-isomer | Foradil
Chemical Information
Molecular Formula C23H30N2O10
CAS Registry Number 200815-49-2
SMILES CC(CC1=CC=C(C=C1)OC)NCC(C2=CC(=C(C=C2)O)NC=O)O.C(C(C(=O)O)O)(C(=O)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Neoplasm16.16.02.001--Not Available
Nephrolithiasis20.04.01.002--
Nervousness19.06.02.003--Not Available
Nocturia20.02.03.001--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.007--
Oral candidiasis11.03.03.004; 07.05.07.001--Not Available
Pain08.01.08.004--
Palpitations02.11.04.012--
Paralysis17.01.04.004--Not Available
Pelvic pain21.10.01.001; 20.02.03.007; 07.01.06.012--
Prostatic specific antigen increased13.23.01.003--Not Available
Pyrexia08.05.02.003--
Pyuria20.08.02.016; 11.01.08.043--Not Available
Rash23.03.13.001--Not Available
Rectal haemorrhage24.07.02.018; 07.12.03.001--
Respiratory disorder22.02.07.002--Not Available
Retroperitoneal haemorrhage24.07.01.017; 07.07.02.002; 12.01.17.018--
Rheumatoid arthritis15.01.03.001; 10.04.06.001--Not Available
Sinusitis22.07.03.007; 11.01.13.005--
Skin discolouration23.03.03.005--Not Available
Skin hypertrophy23.01.04.002--Not Available
Somnolence17.02.04.006; 19.02.05.003--
Supraventricular tachycardia02.03.03.012--
Tachycardia02.03.02.007--Not Available
Tendinous contracture15.07.01.001--Not Available
Tooth abscess11.01.04.003; 07.09.01.003--Not Available
Tremor17.01.06.002--
Urinary tract disorder20.08.01.001--Not Available
Urine abnormality20.02.01.013--Not Available
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages